[go: up one dir, main page]

FI105183B - Menetelmä sydämen vajaatoiminnan hoidossa käyttökelpoisen (-)-[[4-(1,4,5,6-tetrahydro-4-metyyli-6-okso-3-pyridatsinyyli)-fenyyli]hydratsono]propaanidinitriilin valmistamiseksi - Google Patents

Menetelmä sydämen vajaatoiminnan hoidossa käyttökelpoisen (-)-[[4-(1,4,5,6-tetrahydro-4-metyyli-6-okso-3-pyridatsinyyli)-fenyyli]hydratsono]propaanidinitriilin valmistamiseksi Download PDF

Info

Publication number
FI105183B
FI105183B FI932618A FI932618A FI105183B FI 105183 B FI105183 B FI 105183B FI 932618 A FI932618 A FI 932618A FI 932618 A FI932618 A FI 932618A FI 105183 B FI105183 B FI 105183B
Authority
FI
Finland
Prior art keywords
phenyl
methyl
tetrahydro
oxo
pyridazinyl
Prior art date
Application number
FI932618A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932618L (fi
FI932618A0 (fi
Inventor
Pentti Nore
Erkki Honkanen
Reijo Baeckstroem
Tom Wikberg
Heimo Haikala
Jorma Haarala
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919100049A external-priority patent/GB9100049D0/en
Priority claimed from GB919118947A external-priority patent/GB9118947D0/en
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of FI932618L publication Critical patent/FI932618L/fi
Publication of FI932618A0 publication Critical patent/FI932618A0/fi
Priority to FI972077A priority Critical patent/FI109902B/fi
Application granted granted Critical
Publication of FI105183B publication Critical patent/FI105183B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
FI932618A 1991-01-03 1993-06-09 Menetelmä sydämen vajaatoiminnan hoidossa käyttökelpoisen (-)-[[4-(1,4,5,6-tetrahydro-4-metyyli-6-okso-3-pyridatsinyyli)-fenyyli]hydratsono]propaanidinitriilin valmistamiseksi FI105183B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI972077A FI109902B (fi) 1991-01-03 1997-05-15 Menetelmä 6-(4-aminofenyyli)-5-metyylipyridatsin-3(2H)onin puhtaiden enantiomeerien valmistamiseksi

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919100049A GB9100049D0 (en) 1991-01-03 1991-01-03 (-)-6-(4-(dicyanomethylidenehydrazino)phenyl)-4,5-dihydro-5-methylpyridazin-3(2h)one
GB9100049 1991-01-03
GB919118947A GB9118947D0 (en) 1991-09-05 1991-09-05 Method for the optical resolution of racemic 6-(4-amino-phenyl)-methyl-pyridazin-3(2h)one and preparation of optically active derivatives thereof
GB9118947 1991-09-05

Publications (3)

Publication Number Publication Date
FI932618L FI932618L (fi) 1993-06-09
FI932618A0 FI932618A0 (fi) 1993-06-09
FI105183B true FI105183B (fi) 2000-06-30

Family

ID=26298204

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932618A FI105183B (fi) 1991-01-03 1993-06-09 Menetelmä sydämen vajaatoiminnan hoidossa käyttökelpoisen (-)-[[4-(1,4,5,6-tetrahydro-4-metyyli-6-okso-3-pyridatsinyyli)-fenyyli]hydratsono]propaanidinitriilin valmistamiseksi

Country Status (32)

Country Link
US (3) US5424428A (et)
EP (1) EP0565546B1 (et)
JP (2) JP2635445B2 (et)
KR (1) KR100207145B1 (et)
AT (1) ATE119525T1 (et)
AU (1) AU645399B2 (et)
BG (1) BG62002B1 (et)
BR (1) BR1100737A (et)
CA (2) CA2314115C (et)
CY (1) CY1878A (et)
DE (1) DE69201640T2 (et)
DK (1) DK0565546T3 (et)
EE (1) EE02946B1 (et)
ES (1) ES2070627T3 (et)
FI (1) FI105183B (et)
GB (1) GB2251615B (et)
GE (1) GEP19991868B (et)
HK (1) HK117395A (et)
HR (1) HRP921251B1 (et)
HU (1) HU218659B (et)
IE (1) IE72101B1 (et)
IL (2) IL114028A (et)
LU (1) LU90920I2 (et)
LV (1) LV11174B (et)
NO (2) NO300682B1 (et)
NZ (1) NZ241194A (et)
PL (2) PL169415B1 (et)
RO (1) RO111847B1 (et)
RU (1) RU2118317C1 (et)
SI (1) SI9112003A (et)
WO (1) WO1992012135A1 (et)
YU (1) YU48767B (et)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
JP2806192B2 (ja) * 1992-11-02 1998-09-30 日本曹達株式会社 血小板凝集抑制剤
US5856480A (en) * 1994-11-11 1999-01-05 Nippon Soda Co., Ltd. Optically active compound
GB9606474D0 (en) * 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI980901A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
FI981473A7 (fi) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj Menetelmä pulmonaalihypertension hoitamiseksi
GB9915179D0 (en) 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm
FI109659B (fi) 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
CA2387920C (en) 1999-10-22 2008-08-26 Orion Corporation A new use of levosimendan
FI20001542A7 (fi) * 2000-06-29 2001-12-30 Orion Yhtymae Oyj Menetelmä septisen sokin hoitamiseksi
FI20002525A7 (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Tulehduksenvastaisia aineita
FI20002526A7 (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Pyridatsinonijohdannaisten uusi käyttö
FI20002755A0 (fi) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20011464A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
FI20030015A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Menetelmä munuaisten vajaatoiminnan hoitamiseksi
JPWO2004087641A1 (ja) * 2003-03-31 2006-06-29 第一製薬株式会社 ヒドラゾン誘導体
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) * 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
CA2568393A1 (en) * 2004-05-28 2005-12-15 Abbott Laboratories Methods for treating a mammal before, during and after cardiac arrest
CA2599575A1 (en) 2005-03-14 2006-09-21 Orion Corporation A combination treatment for enhancing diuresis
EP1951227B1 (en) 2005-11-14 2017-04-12 Boehringer Ingelheim Vetmedica GmbH Use of pimobendan for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
JP2010516659A (ja) * 2007-01-17 2010-05-20 オリオン コーポレーション 慢性弁膜症治療に使用されるためのレボシメンダン
DK2370070T3 (da) 2008-11-25 2013-12-02 Boehringer Ingelheim Vetmed Pimobendan til anvendelse i behandling af hypertrofisk cardiomyopati hos katte
WO2011007123A1 (en) * 2009-07-14 2011-01-20 Cipla Limited Process for preparing levosimendan and intermediates for use in the process
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
SI3865120T1 (sl) 2013-07-19 2025-12-31 Boehringer Ingelheim Vetmedica Gmbh Konzervirani eterificirani derivati ciklodekstrina, ki vsebujejo tekoč vodni farmacevtski sestavek
CN104418810A (zh) * 2013-09-04 2015-03-18 北京博时安泰科技发展有限公司 一种左西孟旦的合成新路线
CN103554033A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 一种消旋体(±)- 6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的拆分方法
CN103554032A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 高光学纯度(-)-6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的制备方法
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
CN114699528A (zh) 2015-08-13 2022-07-05 布罗德研究所股份有限公司 用于表达pde3a或slfn12的癌症的组合物和方法
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3424908A1 (en) 2017-07-07 2019-01-09 Melody Healthcare Pvt. Ltd. Process for preparation of levosimendan
US9962384B1 (en) * 2017-09-07 2018-05-08 Korea Institute Of Science And Technology Levosimendan compound for preventing or treating tau-related diseases
CN111548310B (zh) * 2020-05-12 2021-07-02 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型及其制备方法
CN111718299B (zh) * 2020-07-23 2023-03-10 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型b及其制备方法
US11760730B2 (en) 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB228004A (en) * 1924-01-24 1925-01-29 Daimler Co Ltd Improvements in locking devices for sliding windows
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS6193169A (ja) * 1984-10-12 1986-05-12 Sankyo Co Ltd ピリダジノン誘導体及びその製法
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
JPH0629254B2 (ja) * 1986-09-08 1994-04-20 帝国臓器製薬株式会社 ピリダジノン誘導体
GB8824458D0 (en) * 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile

Also Published As

Publication number Publication date
EE02946B1 (et) 1996-12-16
JPH09183767A (ja) 1997-07-15
EP0565546A1 (en) 1993-10-20
DK0565546T3 (da) 1995-05-22
RU2118317C1 (ru) 1998-08-27
CA2099262C (en) 2002-03-12
LU90920I2 (en) 2002-07-17
US5569657A (en) 1996-10-29
AU645399B2 (en) 1994-01-13
HRP921251A2 (en) 1995-08-31
YU200391A (sh) 1994-05-10
CA2314115A1 (en) 1992-07-04
LV11174B (en) 1996-12-20
CY1878A (en) 1996-04-05
DE69201640D1 (de) 1995-04-13
IL100553A0 (en) 1992-09-06
ES2070627T3 (es) 1995-06-01
GB2251615A (en) 1992-07-15
GB2251615B (en) 1995-02-08
IE920002A1 (en) 1992-07-15
IL114028A (en) 1996-09-12
YU48767B (sh) 1999-12-27
HRP921251B1 (en) 2000-06-30
BG62002B1 (bg) 1998-12-30
US5512571A (en) 1996-04-30
JP3015748B2 (ja) 2000-03-06
IE72101B1 (en) 1997-03-12
HUT64754A (en) 1994-02-28
EP0565546B1 (en) 1995-03-08
SI9112003A (sl) 1998-10-31
WO1992012135A1 (en) 1992-07-23
NO932367L (no) 1993-06-28
KR100207145B1 (ko) 1999-07-15
FI932618L (fi) 1993-06-09
BR1100737A (pt) 2000-03-21
PL169415B1 (pl) 1996-07-31
IL114028A0 (en) 1995-10-31
LV11174A (lv) 1996-04-20
NO2001021I1 (no) 2001-12-03
GB9127145D0 (en) 1992-02-19
DE69201640T2 (de) 1995-08-10
PL169435B1 (pl) 1996-07-31
JPH06504275A (ja) 1994-05-19
NO300682B1 (no) 1997-07-07
GEP19991868B (en) 1999-12-06
IL100553A (en) 1995-12-31
ATE119525T1 (de) 1995-03-15
RO111847B1 (ro) 1997-02-28
CA2099262A1 (en) 1992-07-04
HK117395A (en) 1995-07-28
NZ241194A (en) 1993-06-25
US5424428A (en) 1995-06-13
BG97915A (bg) 1994-04-29
NO932367D0 (no) 1993-06-28
KR930703266A (ko) 1993-11-29
CA2314115C (en) 2004-03-30
FI932618A0 (fi) 1993-06-09
AU1153592A (en) 1992-08-17
HU9301911D0 (en) 1993-09-28
JP2635445B2 (ja) 1997-07-30
HU218659B (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
FI105183B (fi) Menetelmä sydämen vajaatoiminnan hoidossa käyttökelpoisen (-)-[[4-(1,4,5,6-tetrahydro-4-metyyli-6-okso-3-pyridatsinyyli)-fenyyli]hydratsono]propaanidinitriilin valmistamiseksi
CN115215847B (zh) 一类kras-sos1抑制剂、其制备方法及其应用
JP7473642B2 (ja) Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用
US5244901A (en) 4-pyrimidinecarboxamide derivatives, their preparation and their application in therapy
CA1310966C (en) Substituted 1-(h-imidazol-4-yl)alkyl-benzamides
EP2143715B1 (en) Method for obtaining pure enantiomers of a pyridazinone derivative
SK5782001A3 (en) Benzoylpyridazine derivative, process for the preparation thereof and pharmaceutical composition containing same
US5356916A (en) 1,2,4-oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity
EP0201988B1 (en) Dihydropyridazinone derivatives
EP0381235B1 (en) Pyrrolidine compound and pharmaceutical use
JPH03141264A (ja) 強心活性およびベータ遮断活性を有するピリダジノン
US5686452A (en) Indane derivative and processes for preparing the same
HK1001396B (en) Pyrimidinylpyrazole derivative
HK1001396A1 (en) Pyrimidinylpyrazole derivative
JPH06100541A (ja) ピラゾリノン誘導体

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20010019

PC Transfer of assignment of patent

Owner name: ORION CORPORATION

Free format text: ORION CORPORATION

SPCL Withdrawal, rejection or dismissal of a supplementary protection certificate

Free format text: SPC L20010019

Spc suppl protection certif: L20010019